Jayanth Panyam

List of Publications by Year
in descending order

83	11,674	66343 42	56724 83
papers	citations	h-index	g-index

85	85	85	15163
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Reviews, 2003, 55, 329-347.	13.7	2,892
2	Rapid endoâ€•lysosomal escape of poly(DLâ€•lactideâ€•<i>co</i>glycolide) nanoparticles: implications for drug and gene delivery. FASEB Journal, 2002, 16, 1217-1226.	0.5	950
3	Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. Journal of Controlled Release, 2002, 82, 105-114.	9.9	846
4	Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. International Journal of Pharmaceutics, 2002, 244, 105-115.	5.2	505
5	Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles. Journal of Controlled Release, 2003, 92, 173-187.	9.9	446
6	Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharmaceutical Research, 2003, 20, 212-220.	3.5	420
7	Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. Journal of Controlled Release, 2009, 136, 21-29.	9.9	297
8	The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials, 2010, 31, 358-365.	11.4	287
9	Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(d,l-lactide-co-glycolide) nanoparticles. International Journal of Pharmaceutics, 2003, 262, 1-11.	5.2	285
10	Solidâ€•state Solubility Influences Encapsulation and Release of Hydrophobic Drugs from PLGA/PLA Nanoparticles. Journal of Pharmaceutical Sciences, 2004, 93, 1804-1814.	3.3	249
11	Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. Journal of Controlled Release, 2010, 141, 137-144.	9.9	239
12	Polymeric nanoparticles for siRNA delivery and gene silencing. International Journal of Pharmaceutics, 2009, 367, 195-203.	5.2	229
13	Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Advanced Drug Delivery Reviews, 2013, 65, 1731-1747.	13.7	218
14	Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials, 2009, 30, 859-866.	11.4	212
15	Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials, 2013, 34, 5163-5171.	11.4	210
16	CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. Journal of Controlled Release, 2013, 171, 280-287.	9.9	168
17	Sustained Cytoplasmic Delivery of Drugs with Intracellular Receptors Using Biodegradable Nanoparticles. Molecular Pharmaceutics, 2004, 1, 77-84.	4.6	166
18	Folic Acid Functionalized Nanoparticles for Enhanced Oral Drug Delivery. Molecular Pharmaceutics, 2012, 9, 2103-2110.	4.6	149

#	Article	IF	Citations
19	Nanoparticles for Cellular Drug Delivery: Mechanisms and Factors Influencing Delivery. Journal of Nanoscience and Nanotechnology, 2006, 6, 2651-2663.	0.9	142
20	Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials, 2018, 164, 38-53.	11.4	133
21	Flash Nanoprecipitation: Particle Structure and Stability. Molecular Pharmaceutics, 2013, 10, 4367-4377.	4.6	119
22	Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 214-222.	4.3	118
23	Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. International Journal of Pharmaceutics, 2006, 320, 150-156.	5.2	117
24	Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response. Journal of Controlled Release, 2019, 294, 268-278.	9.9	114
25	Injectable Sustained Release Microparticles of Curcumin: A New Concept for Cancer Chemoprevention. Cancer Research, 2010, 70, 4443-4452.	0.9	112
26	Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials, 2011, 32, 6606-6613.	11.4	108
27	Surfactantâ€“Polymer Nanoparticles Overcome P-Glycoprotein-Mediated Drug Efflux. Molecular Pharmaceutics, 2007, 4, 730-738.	4.6	102
28	Surfactantâ˘'Polymer Nanoparticles Enhance the Effectiveness of Anticancer Photodynamic Therapy. Molecular Pharmaceutics, 2008, 5, 795-807.	4.6	96
29	Surfactant-polymer Nanoparticles: A Novel Platform for Sustained and Enhanced Cellular Delivery of Water-soluble Molecules. Pharmaceutical Research, 2007, 24, 803-810.	3.5	94
30	Polymerâ€surfactant nanoparticles for sustained release of waterâ€soluble drugs. Journal of Pharmaceutical Sciences, 2007, 96, 3379-3389.	3.3	91
31	Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting. Molecular Cancer Therapeutics, 2018, 17, 1196-1206.	4.1	87
32	Effective Elimination of Cancer Stem Cells by Magnetic Hyperthermia. Molecular Pharmaceutics, 2013, 10, 1432-1441.	4.6	84
33	Targeting Intracellular Targets. Current Drug Delivery, 2004, 1, 235-247.	1.6	80
34	Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Research and Treatment, 2017, 49, 1140-1152.	3.0	68
35	Highly Loaded, Sustained-Release Microparticles of Curcumin for Chemoprevention. Journal of Pharmaceutical Sciences, 2011, 100, 2599-2609.	3.3	63
36	Weighing up gene delivery. Nature Nanotechnology, 2013, 8, 805-806.	31.5	63

#	Article	IF	Citations
37	Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy. Nanoscale, 2018, 10, 20851-20862.	5.6	59
38	Improving Payload Capacity and Anti-Tumor Efficacy of Mesenchymal Stem Cells Using TAT Peptide Functionalized Polymeric Nanoparticles. Cancers, 2019, 11, 491.	3.7	52
39	Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. International Journal of Nanomedicine, 2014, 9, 2933.	6.7	51
40	Triptolide suppresses the<i>in vitro</i>and<i>in vivo</i>growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling. Oncotarget, 2017, 8, 26927-26940.	1.8	51
41	Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin. Drug Delivery and Translational Research, 2014, 4, 344-352.	5.8	48
42	Interfacial Activity Assisted Surface Functionalization: A Novel Approach To Incorporate Maleimide Functional Groups and cRGD Peptide on Polymeric Nanoparticles for Targeted Drug Delivery. Molecular Pharmaceutics, 2010, 7, 1108-1117.	4.6	47
43	Enhanced Photodynamic Therapy and Effective Elimination of Cancer Stem Cells Using Surfactantâ€“Polymer Nanoparticles. Molecular Pharmaceutics, 2014, 11, 3186-3195.	4.6	40
44	Enhancing therapeutic efficacy through designed aggregation of nanoparticles. Biomaterials, 2014, 35, 7860-7869.	11.4	40
45	Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 715-724.	2.5	38
46	Identification of a novel monoclonal antibody recognizing CD133. Journal of Immunological Methods, 2010, 361, 110-115.	1.4	33
47	Immunotoxin targeting CD133+ breast carcinoma cells. Drug Delivery and Translational Research, 2013, 3, 195-204.	5.8	31
48	Nanoparticles Containing High Loads of Paclitaxel-Silicate Prodrugs: Formulation, Drug Release, and Anticancer Efficacy. Molecular Pharmaceutics, 2015, 12, 4329-4335.	4.6	30
49	Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer. Scientific Reports, 2019, 9, 12492.	3.3	30
50	Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. Molecular Pharmaceutics, 2019, 16, 1200-1210.	4.6	30
51	Coreâ€“shell Particles for the Dispersion of Small Polar Drugs and Biomolecules in Hydrofluoroalkane Propellants. Pharmaceutical Research, 2008, 25, 289-301.	3.5	29
52	Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine. Cancer Research, 2017, 77, 1465-1475.	0.9	28
53	TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy. Molecular Pharmaceutics, 2020, 17, 2109-2124.	4.6	28
54	Nanoparticle-mediated p53 gene therapy for tumor inhibition. Drug Delivery and Translational Research, 2011, 1, 43-52.	5.8	27

#	Article	IF	Citations
55	Freeze concentration-induced PLGA and polystyrene nanoparticle aggregation: Imaging and rational design of lyoprotection. Journal of Controlled Release, 2017, 248, 125-132.	9.9	27
56	Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer. Future Drug Discovery, 2019, 1, FDD8.	2.1	27
57	Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors. Oncotarget, 2016, 7, 57752-57769.	1.8	27
58	A Review of Select Recent Patents on Novel Nanocarriers. Recent Patents on Drug Delivery and Formulation, 2009, 3, 137-142.	2.1	26
59	Preparation of siRNA-Encapsulated PLGA Nanoparticles for Sustained Release of siRNA and Evaluation of Encapsulation Efficiency. Methods in Molecular Biology, 2012, 906, 311-319.	0.9	25
60	Silicate Esters of Paclitaxel and Docetaxel: Synthesis, Hydrophobicity, Hydrolytic Stability, Cytotoxicity, and Prodrug Potential. Journal of Medicinal Chemistry, 2014, 57, 2368-2379.	6.4	25
61	Encapsulation of Andrographolide in poly(lactide-co-glycolide) Nanoparticles: Formulation Optimization and in vitro Efficacy Studies. Frontiers in Bioengineering and Biotechnology, 2021, 9, 639409.	4.1	23
62	The effects of collagen-rich extracellular matrix on the intracellular delivery of glycol chitosan nanoparticles in human lung fibroblasts. International Journal of Nanomedicine, 2017, Volume 12, 6089-6105.	6.7	22
63	Polymer-surfactant nanoparticles for improving oral bioavailability of doxorubicin. Journal of Pharmaceutical Investigation, 2017, 47, 65-73.	5.3	21
64	Chemopreventive efficacy of curcumin-loaded PLGA microparticles in a transgenic mouse model of HER-2-positive breast cancer. Drug Delivery and Translational Research, 2018, 8, 329-341.	5.8	20
65	Fe$_{3}$O$_{4}$ Incorporated AOT-Alginate Nanoparticles for Drug Delivery. IEEE Transactions on Magnetics, 2008, 44, 2800-2803.	2.1	17
66	Nanoengineering of Mesenchymal Stem Cells via Surface Modification for Efficient Cancer Therapy. Advanced Therapeutics, 2019, 2, 1900043.	3.2	17
67	Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Scientific Reports, 2021, 11, 3346.	3.3	17
68	Identification and characterization of a novel scFv recognizing human and mouse CD133. Drug Delivery and Translational Research, 2013, 3, 143-151.	5.8	16
69	A Pharmacokinetic Model for Quantifying the Effect of Vascular Permeability on the Choice of Drug Carrier: A Framework for Personalized Nanomedicine. Journal of Pharmaceutical Sciences, 2015, 104, 1174-1186.	3.3	14
70	Epithelial Proinflammatory Response and Curcumin-Mediated Protection from Staphylococcal Toxic Shock Syndrome Toxin-1. PLoS ONE, 2012, 7, e32813.	2.5	13
71	Intranasal delivery of liposomal indole-3-carbinol improves its pulmonary bioavailability. International Journal of Pharmaceutics, 2014, 477, 96-101.	5.2	13
72	A novel terpenoid class for prevention and treatment of <i>KRAS</i>â€driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems. Molecular Carcinogenesis, 2020, 59, 886-896.	2.7	9

#	Article	IF	Citations
73	Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index. Molecular Pharmaceutics, 2015, 12, 2912-2923.	4.6	8
74	Chemopreventive efficacy of oral curcumin: a prodrug hypothesis. FASEB Journal, 2019, 33, 9453-9465.	0.5	8
75	Exploiting antibody biology for the treatment of cancer. Immunotherapy, 2020, 12, 255-267.	2.0	7
76	Incorporation of Phospholipids Enhances Cellular Uptake and Retention of Surfactant-Polymer Nanoparticles. Journal of Biomedical Nanotechnology, 2007, 3, 291-296.	1.1	6
77	Cancer stem cells and strategies for targeted drug delivery. Drug Delivery and Translational Research, 2021, 11, 1779-1805.	5.8	6
78	Attenuated Salmonella enterica Typhimurium reduces tumor burden in an autochthonous breast cancer model. Anticancer Research, 2015, 35, 843-9.	1.1	6
79	Evaluation of Vaginal Drug Levels and Safety of a Locally Administered Glycerol Monolaurate Cream in Rhesus Macaques. Journal of Pharmaceutical Sciences, 2017, 106, 1821-1827.	3.3	4
80	Image-guided drug delivery in lung cancer. Drug Delivery and Translational Research, 2012, 2, 31-44.	5.8	2
81	Inhibition of Chlamydia trachomatis Growth During the Last Decade: A Mini-Review. Mini-Reviews in Medicinal Chemistry, 2018, 18, 1363-1372.	2.4	2
82	Cancer stem cells. Drug Delivery and Translational Research, 2013, 3, 111-112.	5.8	1
83	Phospholipid Nanoparticles: Process Optimization Using Factorial Design and Atomic Force Microscopy. Journal of Biomedical Nanotechnology, 2007, 3, 394-400.	1.1	1